<DOC>
	<DOCNO>NCT00545012</DOCNO>
	<brief_summary>This long-term open label follow-up trial give pediatric subject suffer typical absence CAE JAE opportunity continue levetiracetam treatment participation pilot study ( study N162 ) double-blind study ( study N163 ) . Safety efficacy data obtain .</brief_summary>
	<brief_title>A Safety Efficacy Follow-up Study With Levetiracetam Children ( 4-17 Years Old ) Suffering From Absence Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy , Absence</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Male/female 417 year old participate study N162 study N163 suffer typical absence 3 Hz spikewave discharge , without tonicclonic seizure , CAE JAE expect reasonable benefit ( efficacy tolerability ) levetiracetam long term administration allergy/intolerance pyrrolidine derivative and/or excipients use &gt; 2 concomitant antiepileptic treatment valproate , ethosuximide lamotrigine</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
</DOC>